The ARHGEF10 Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human near-haploid chronic myeloid leukemia cell line, designed for loss-of-function studies of the ARHGEF10 gene. This product provides a heterogeneous pool of cells carrying targeted gene disruptions, enabling robust population-level analysis of ARHGEF10-dependent processes without the need for single-cell clone isolation. As a polyclonal knockout model, it reflects the diversity of editing outcomes, making it particularly suitable for assays that assess broad cellular phenotypes such as migration, adhesion, and cytoskeletal reorganization. Researchers can employ this model to dissect the functional consequences of ARHGEF10 ablation in a genetically tractable human cell system.
The HAP1 host cell line originates from the KBM-7 chronic myeloid leukemia line, characterized by BCR-ABL expression, p53 deficiency, and a near-haploid karyotype that simplifies genetic manipulation and phenotypic interrogation. This background provides a cancer-relevant context for studying signaling pathways linked to cell proliferation, survival, and motility, while the haploid genome facilitates efficient CRISPR/Cas9-mediated gene disruption. The resulting ARHGEF10 knockout cells retain the essential features of HAP1 cells, including their adherent morphology and rapid growth, making them a convenient platform for high-throughput screening and detailed mechanistic investigations.
ARHGEF10 functions as a guanine nucleotide exchange factor (GEF) that specifically activates RhoA by promoting GTP loading, thereby driving actin stress fiber formation and cellular contractility through the RhoA-ROCK-LIMK-cofilin cascade. Activation of ARHGEF10 occurs downstream of integrin-mediated adhesion, receptor tyrosine kinases such as EGFR and PDGFR, and G protein-coupled receptors, integrating extrinsic signals with cytoskeletal dynamics. In addition to its role in actin regulation, ARHGEF10 interacts with the microtubule motor protein KIF5A and myelin protein zero (MPZ), linking it to intracellular transport and myelination processes. This dual functionality positions ARHGEF10 at the crossroads of cytoskeletal organization and neuronal cell biology, with implications for axon guidance and peripheral nerve integrity.
Disruption of ARHGEF10 in HAP1 cells offers a powerful model to explore RhoA-mediated cytoskeletal regulation in the context of a leukemic cell line with compromised p53 function. The knockout phenotype may manifest as altered F-actin organization, reduced stress fiber formation, impaired focal adhesion dynamics, and defects in cell migration, all of which can be quantitatively assessed using established assays such as scratch wound healing and Transwell invasion. Furthermore, the loss of ARHGEF10 may perturb the interaction with KIF5A, providing a cell-based system to study motor protein-dependent transport and the molecular basis of myelination. This model is particularly relevant for investigating pathways implicated in Charcot-Marie-Tooth disease type 4 and other peripheral neuropathies.
Typical applications include Western blot and RT-qPCR confirmation of ARHGEF10 disruption, RhoA-GTP pull-down assays to measure activation status, and immunofluorescence staining for F-actin, focal adhesion markers, and tubulin. Live-cell imaging can capture dynamic changes in cytoskeletal remodeling and migration in real time. The polyclonal nature of the product supports drug screening efforts targeting the Rho-ROCK-LIMK pathway, as well as co-immunoprecipitation experiments to validate ARHGEF10-KIF5A complexes. For further technical specifications and ordering information, please contact Ascent Research.
